NVP-AUY922 is an experimental drug candidate for the treatment of cancer. It was discovered through a collaboration between The Institute of Cancer Research and the pharmaceutical company Vernalis and licensed to Novartis. It is currently in Phase II clinical trials. NVP-AUY922 is an inhibitor of heat shock protein 90 (Hsp90), which is a chaperone protein that plays a role in the modification of a variety of proteins that have been implicated in oncogenesis. NVP-AUY922 has shown promising activity in preclinical testing against several different tumor types.
Contact：Wuhan Sun-shine Bio-technologyCorporation Limited Add: Building C16, No.388Gaoxin 2Road, East Lake Hi-tech Development Zone, Wuhan 430200, China Tel: +86-27-65522452 QQ：1973737790 Web:http://www.sun-shinechem.com
| 
_747412-49-3.png)